Vivani Medical, Inc. (NASDAQ:VANI) announced that the U.S. FDA has cleared its Investigational New Drug Application for NPM-119, paving the way for the commencement of the LIBERATE-1 Phase 1 trial.

While islet cell transplants allow some diabetics to forgo daily insulin injections, those people have to take immunosuppressive drugs in order to keep the cells from being rejected. A new implant, ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

Long-acting reversible contraception (LARC) is widely regarded as a transformative advancement in reproductive healthcare. Offering unparalleled efficacy and ease of use, LARC methods such as ...